Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer

Model scores of the 29,894 trials active now.

Model score 26% for any early termination, 28% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-06-16. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cell lungsmall celllung cancernon smallfunction
  Phrases that lowered it: linecompletedtreatmentreactionsevere
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 12.0% (raises risk) · Sponsor's track record
• Collaborators: 3 (lowers risk) · Design
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 57 (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Drug's FAERS reports marked serious: 97.8% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: not given (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 166 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 22.3% (raises risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 1646 (raises risk) · Drug's FDA history
• Disease area, respiratory: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer NCT01038752 · started 2010 · scored riskier than 93% of active trials terminated
• Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. NCT01750281 · started 2012 · scored riskier than 47% of active trials completed
• Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy NCT01038661 · started 2009 · scored riskier than 58% of active trials completed
• Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer NCT01350817 · started 2011 · scored riskier than 87% of active trials completed
• Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer NCT01107444 · started 2010 · scored riskier than 19% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.